What are you searching for ?

Business

Leqembi: A Ray of Hope for Alzheimer’s Patients Amidst Challenges

Leqembi: A Ray of Hope for Alzheimer’s Patients Amidst Challenges

Leqembi, a drug from Biogen and Eisai, presents a potential breakthrough for Alzheimer’s patients, particularly those in the earliest stages of the disease. Approved in July 2023, it aims to slow the progression of cognitive decline, allowing patients more time to live independently. However, the journey to accessing this treatment is fraught with challenges.

 

The Promise of Leqembi

Leqembi is not a cure but offers a lifeline by moderately slowing memory and cognitive decline. For patients like Missie Meeks, who was diagnosed with early-stage Alzheimer’s before her 50th birthday, the drug has been pivotal in maintaining a semblance of normalcy. “It’s extending my time of a normal life,” Meeks shared.

 

Challenges in Access

Despite its promise, accessing Leqembi is complex. Patients face hurdles such as insurance coverage issues, the need for diagnostic tests, and regular brain scans. The scarcity of neurologists further complicates the process. Some hospitals lack the infrastructure to support the influx of patients eligible for the treatment.

 

Risks and Concerns

Leqembi is associated with risks like brain swelling and bleeding, leading some doctors to be cautious in prescribing it. Dr. Julio Rojas from UCSF Health highlights the ongoing challenge of determining how best to use and monitor the drug.

 

Diagnosis and Eligibility

The process of diagnosing Alzheimer’s and determining eligibility for Leqembi is lengthy. It involves PET scans or spinal fluid tests to identify amyloid plaques, a hallmark of Alzheimer’s. Even after diagnosis, insurance barriers can prolong the wait for treatment.

 

Infusion Difficulties

Once approved, patients must receive biweekly infusions of Leqembi. However, the limited number of infusion centers poses logistical issues, especially for those living far from available clinics.

 

Moving Forward

Despite these obstacles, the number of patients receiving Leqembi is growing. Sales reached nearly $60 million in the first half of 2024, indicating increasing uptake. Biogen and Eisai are working on more accessible forms of the drug, including a monthly maintenance dose and a subcutaneous version.



Crypto and Metals



btc us108,814 USDBitcoin
eth us2,565.81 USDEthereum
xrp us2.24430 USDXRP
xau us3,347.73 USDGold Ounce
xag us36.4054 USDSilver Ounce
xpd us1,146.88 USDPalladium Ounce
xpt us1,405.64 USDPlatinum Ounce


Important Stocks >>




Latest News

Business

U.S. Treasury yields experienced a notable rise early Wednesday as markets analyzed the potential impact of President Donald Trump’s ..

Business

While the U.S. luxury market faces headwinds, one category continues to glitter: jewelry. According to a recent Citigroup analysis, ..

Economic

Germany’s annual inflation rate dropped unexpectedly to 2% in June, hitting the European Central Bank’s (ECB) long-standing target. The ..

Business

In the rapidly evolving space race, Europe is betting on its own satellite operator, Eutelsat, to challenge the dominance ..